Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statemen

Company Update Dr. Michael Perry

December 14, 2021 Exhibit 99.1

Certain statements in this presentation

and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation,

including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of

success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the

uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVD-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved

products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting

risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking

statements as predictions of future events. More information concerning us and such risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form

10-Q for the quarter ended June 30, 2021 and our most recent Annual Report on Form 10-K for the year ended June 30, 2020. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a

result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. In the United States, RECELL is approved for use

in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited

by United States law to investigational use only). Legal Disclaimers

Fiscal 2022 RECELL total net

revenue growth of 105% vs prior year Cumulative U.S. commercial sales since September 2018 FDA approval exceeding $46M Soft Tissue Pivotal Trial: 94% Enrolled Vitiligo Pivotal Trial: 83% enrolled and the remaining 17% scheduled before year-end

Transitional Pass-Through Payment Application Approved by CMS for Reimbursement in the Outpatient Setting Effective January 1st, 2022 FDA Approval of Pediatric Label Expansion New Ease of Use RECELL Device Submitted to FDA for Review Completion of

RECELL Systems delivery to Biomedical Advanced Research and Development Authority (BARDA) under Vendor Managed Inventory Plan for emergency preparedness ($7.6M revenue) AVITA completed $69.1M Public Offering of Stock on NASDAQ Key Additions of

Executives: Michael Holder, CFO & Kathy McGee, COO Key Accomplishments Since Last Shareholder Meeting Quarters referenced in calendar year. As of January 1, 2022 Avita Medical will report on a calendar year basis. Accomplishments

AVITA Leadership Team Dr. Michael S.

Perry CEO >30 years experience Affiliations: Michael Holder CFO >30 years experience Affiliations: Donna Shiroma General Counsel >20 years experience Affiliations: Andrew Quick CTO >25 years experience Affiliations: Kathy

McGee COO >25 years experience Affiliations: Erin Liberto CCO >20 years experience Affiliations:

One Platform. Endless Possibilities. In

the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. RECELL enables regeneration of healthy skin Patch of healthy

skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient RECELL delivers healthy skin cells Free cells modulate and catalyze the healing process Technology platform benefits a wide array

of skin defects and wounds irrespective of etiology Vitiligo Burns / Scalds Scar Revision Infectious Disease Regenerative Dermatology Trauma Chronic Wounds Cancer Reconstruction Genodermatoses SKIN RESTORED

Development Pipeline and Growth

Innovation New Device: Improved Ease of

Use New Device: Fully Automated INDICATION DISCOVERY FEASIBILITY PIVOTAL APPROVAL Regenerative Therapeutics - Wounds & Dermatology (Current Platform) Acute Thermal Burns (U.S.) RECELL Japan Vitiligo (U.S.) Soft Tissue Reconstruction

(U.S.) Early-Stage Research Programs Epidermolysis Bullosa Rejuvenation Focused Pipeline with Strong Growth Potential In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States

law to investigational use; or (2) otherwise prohibited. CONCEPT DESIGN APPROVAL SUBMISSION Focused Effort on Business Development to Supplement Pipeline

EXISTING PLATFORM NEW PLATFORMS: CELL

BASED GENE THERAPY > $22 Billion in Combined TOTAL ADDRESSABLE MARKET Market Opportunity of Pipeline Exceeds $22 Billion Skin cells are genetically modified ~$6.8B Opportunity ~$15.8B Opportunity Burns Soft Tissue Vitiligo Epidermolysis Bullosa $

Current Platform: Efficacy is Well

Demonstrated Highly De-risked Pipeline with >15,000 Patients Treated Globally In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2)

otherwise prohibited. Patients (in Published Studies) Number of Publications & Presentations ACUTE WOUNDS (Including Thermal Burns) 1,772 206 DEFECTS/ VITILIGO 453 57 CHRONIC WOUNDS 143 17 A Common Goal: Full Skin Restoration

(Re-epithelialization and Re-pigmentation) PRODUCT IS WELL STUDIED

> $46 Million in U.S. RECELL

Revenue Since Approval 78% Burn Sites Activated 87% Burn Surgeons Certified Accomplishments Since Approval Continued Strong Adoption Despite COVID Headwinds *Data is compiled based on information voluntarily provided by our customers and is subject

to change. Procedures* Sites/Surgeons >4,500 Procedures* As of Sept 30, 2021

AVITA will ensure broad commercial

payer acceptance & coverage before pursuing a full commercial launch This is a Medicare specific code, which we estimate covers ~ 15% of patient lives C1832: Autograft suspension, including cell processing and application, and all system

components Code provides additional payment which offsets the cost of the device for Medicare beneficiaries over a 2-3 year period before converting to a permanent code New C-Code Provides Additional Payment in the Outpatient Setting The New Code is

not Indication (Burns) Specific and Lays the Foundation for Growth in Soft Tissue The Centers for Medicare and Medicaid Services (CMS) created a new technology Transitional Pass-Through (TPT) Payment - C Code for billing RECELL devices when used in

procedures performed in the hospital outpatient and ambulatory surgery center (ASC) settings as of Jan 1 2022

New Ease of Use Device Submitted for

FDA Approval * Market Research March 2020 HCPs N=15 Only 1 Set of Hands Required in the Sterile Field; Steps Reduced By 1/3rd Reduced number of steps New Device Simplified Process Improved Usability 94% of users of the RECELL System believe it will

reduce their workload/allow them to perform other duties*

FDA Approval in Pediatric

Full-Thickness & Larger Burns ~25% of all burns occur in children Instructions for Use. RECELL Autologous Cell Harvesting Device NBR - National Burns Repository * N = 41, "will significantly or somewhat impact RECELL

usage" 80% of RECELL Customers Stated that these New Label Enhancements Will Positively Impact Their Usage of RECELL NUMBER OF TREATMENTS 3.6 1.6 NUMBER OF TREATMENTS 5.9 2.4 NBR Control RECELL 56% fewer mean procedures with RECELL (N=284) p

< 0.0001 Adults with >50% TBSA 60% fewer mean procedures with RECELL (N=318) p < 0.0001 FEWER PROCEDURES REQUIRED FOR DEFINITIVE CLOSURE VS CONVENTIONAL AUTOGRAFT1 Pediatric Patients

Furue M, Yamazaki S, Jimbow K,

Tsuchida T, Amagai M, Tanaka T et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multi-center, hospital-based study. J Dermatol. 2011 April; 38(4):310-20, Japan Health System Review, 2018. Additional

estimates based on data from 2016 JSBI National Burns Repository, https://injuryprevention.bmj.com/content/26/Suppl_2/i36#F2 and Cosmotec estimates Japan - PMDA Review in the Final Phases Incidence of Burns Needing Medical Treatment in Japan

Severe Burns (defined as hospital admissions of burns that may require grafting) Target: Severe Burns Treated at Burn Centers ~1,400 ~6,000 ~250,000 PATIENTS PATIENTS PATIENTS BACKGROUND Reimbursement Anticipated in June 2022 with Commercial Launch

Following Thereafter PATIENT FUNNEL - BURNS ADDRESSABLE MARKET INDICATION: Burns Soft Tissue and Vitiligo to Follow Based on U.S. Pivotal Clinical Data LAUNCH: Following Ministry of Health Labour and Welfare (MHLW) decision on reimbursement pricing,

anticipated June 2022 AVITA Commercial Partner: COSMOTEC, an M3 Company

Vitiligo: Unmet Need, No

FDA-Approved Products Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017. Willingness-to-Pay and Quality of Life in Patients with Vitiligo. Radtke, et al. BJD. 2009. SIGNIFICANT UNMENT NEED

Up to 2% of the population affected (~6.5M in the US) Vitiligo impacts quality of life (QoL) - 25% of patients with vitiligo reported a DLQI >10, which indicates severe QoL reductions, compared with 34% in psoriasis patients No FDA-approved

medical treatments; extremely low patient and physician satisfaction with existing products LIMITED TREATMENT OPTIONS In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States

law to investigational use; or (2) otherwise prohibited. Phototherapy 2-3 treatments / week for a few months to over a year Typically combined with a topical drug Not Durable Melanocyte-Keratinocyte Transplantation For repigmentation of stable

lesions Requires substantial laboratory equipment Performed rarely and only at 3 highly specialized academic centers in the United States

Blinded, Randomized, Study

Evaluating RECELL for Repigmentation of Stable Vitiligo in 23 Patients Vitiligo Study is Close to Completion In the United States, RECELL is not approved for treatment of vitiligo. Patient from a Prior Study at 6 MONTHS RECELL-treated area was 100%

re-pigmented RECELL treated Negative Control Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, van der Veen JW, Wolkerstorfer A. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and

piebaldism patients: a randomized controlled pilot study. Journal of the American Academy of Dermatology. 2015 Jul;73(1):170-2. FDA Submission Expected in H2 22 with Approval in H2 23 Number of Subjects POTENTIAL RECELL BENEFITS For

Stable Vitiligo: Segmental & Non-Segmental Durable: One-time treatment N=23

Early Completion of Soft Tissue

Reconstruction Trial Clinical trial demonstrates use of less donor skin without compromising healing outcomes relative to conventional autografting In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either

(1) limited by United States law to investigational use; or (2) otherwise prohibited. COVID19 IMPACT N=65 Patient treated for necrotizing fasciitis Photos courtesy of Kevin Foster, Valleywise Health Medical Center FDA Submission Expected in H2

22 with Approval in H2 23 TREATMENT DAY 1 YEAR POST-RECELL TREATMENT

Soft Tissue Synergies with Current

Commercial Burn Focus In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not

approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved. ~50% of Burn Centers are also Level 1 / Level 2 Trauma Centers Expanded Acute Wounds Sales Team Will Target a Total of 366

Centers Reimbursement in Place Able to leverage existing CPT & Outpatient C Code 136 Burn Centers (Current Target) +230 High Volume Trauma Centers (Future Expansion) Same Treatment Protocol to Burns Consistent treatment protocol across acute

injuries Same Unmet Needs as Burns Reduction of donor site morbidity & donor site requirements are top unmet needs Large opportunity that leverages existing burns infrastructure

RECELL in Genetic Skin Defects and

Rejuvenation CURRENT PLATFORM FUTURE PLATFORM Treatment using RECELL for harvesting and direct reintroduction of the patient's own healthy skin cells RECELL as a platform for treatment using the patient's corrected skin cells Patch of

healthy skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient Skin processed using the RECELL System Patch of skin removed from patient Enhanced autologous skin cells are reintroduced

to patient Gene editing for debilitating orphan skin disorder Molecular reversal of aging for skin rejuvenation Skin cells are genetically modified In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either

(1) limited by United States law to investigational use; or (2) otherwise prohibited.

Cell Based Gene Therapy Development

Activity Study Objectives: Develop a Spray-on' suspension delivery system of modified cells and establish proof-of-concept Target IND-enablement by establishing preclinical evidence of safety and dosing Proof of Concept FDA Interaction

IND-enabling Studies First-in-human (IND) Four key steps

Exploring Cell-Based Gene Therapy

for Epidermolysis Bullosa In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. THE CHALLENGE THE OPPORTUNITY

DEBILITATING Skin fragility, disability, cancer HIGH UNMET NEED No FDA-approved treatment, only palliative measures COST BURDEN Care of $200K-$500K per year per patient CURATIVE: Technology for precise correction of genetic defect & banking for

future use (vs ameliorating symptoms) EFFICIENT: Suspension-based approach eliminates growth & transport of fragile skin sheets CONVENIENT: Suspension-based product simplifies application onto patient wounds (vs surgical anchoring of epidermal

sheets which can result in issues with "take rates"

Patented RNA technology for delivery

of telomerase enzyme to aged cells Demonstrated reversal of aging and return of functionality in cells of progeria patients (human model of accelerated aging) Patented and proprietary Spray-On Skin Cells technology and device (RECELL) Expertise in

skin regeneration, including in preclinical models Strong track record and expertise in clinical development and commercialization Exploring Novel RNA-Based Approach for Rejuvenation *1. 2020 Plastic Surgery Statistics Report, 2. 2020 Plastic

Surgery Statistics Report (Defined as Facelifts, Ablative Laser, Dermabrasion, Non-Surgical Skin Tightening) In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited

by United States law to investigational use; or (2) otherwise prohibited. Sponsored research exploring use of telomerase for molecular reversal of skin cell aging Patient Funnel and Addressable Market ~1M ~8.3M PEOPLE/Yr PATIENTS/Yr $15 Billion TAM

People Who Underwent Facial Aesthetic Procedures Aimed at Improving Skin Tightness, Texture & Evenness in Skin Tone 1 Target: People Who Undergo Aggressive Facial Lifting & Tightening Procedures2

12 Months Ended June 30 (USD in